Anetumab ravtansine

Drug Profile

Anetumab ravtansine

Alternative Names: Anti-mesothelin antibody-drug conjugate BAY 94-9343; BAY-94-9343; BAY-94-9343-SPDB-DM4

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; ImmunoGen; MorphoSys; National Cancer Institute (USA)
  • Class Antineoplastics; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Mesothelioma; Pancreatic cancer; Solid tumours
  • Phase I Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 11 May 2017 Phase-II clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT03023722)
  • 26 Apr 2017 Phase-I/II clinical trials in Mesothelioma (Second-line therapy or greater, Combination therapy) in USA (IV) before April 2017 (NCT03126630)
  • 07 Apr 2017 Bayer plans a phase I trial for Solid tumours (Late-stage disease, Recurrent, Combination therapy) in USA, Australia, Belgium, Canada, France, Germany, Singapore and Spain (NCT03102320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top